Literature DB >> 7028791

Evaluation of intramuscular levonantradol and placebo in acute postoperative pain.

A K Jain, J R Ryan, F G McMahon, G Smith.   

Abstract

Double-blind administration of a single intramuscular dose of 1.5, 2.0, 2.5, or 3.0 mg levonantradol or placebo to 56 patients with moderate to severe postoperative or trauma pain showed significant analgesic effects of each dose of levonantradol as compared to placebo (P less than 0.05). However, no significant dose response was observed. Compared to 2/16 patients on placebo, 23/40 patients (57 per cent) on levonantradol reported one or more side effect. Drowsiness was most frequent. Dry mouth, dizziness, "weird dreams," mild hallucinations, nervousness, apprehension and confusion occurred less frequently. Changes in resting heart rate and blood pressure were minor and general acceptability was good.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7028791     DOI: 10.1002/j.1552-4604.1981.tb02610.x

Source DB:  PubMed          Journal:  J Clin Pharmacol        ISSN: 0091-2700            Impact factor:   3.126


  29 in total

Review 1.  Are cannabinoids an effective and safe treatment option in the management of pain? A qualitative systematic review.

Authors:  F A Campbell; M R Tramèr; D Carroll; D J Reynolds; R A Moore; H J McQuay
Journal:  BMJ       Date:  2001-07-07

2.  Cannabis and endocannabinoid modulators: Therapeutic promises and challenges.

Authors:  Igor Grant; B Rael Cahn
Journal:  Clin Neurosci Res       Date:  2005

Review 3.  The Impact of Perioperative Cannabis Use: A Narrative Scoping Review.

Authors:  Karim S Ladha; Varuna Manoo; Ali-Faizan Virji; John G Hanlon; Alexander Mclaren-Blades; Akash Goel; Duminda N Wijeysundera; Lakshmi P Kotra; Carlos Ibarra; Marina Englesakis; Hance Clarke
Journal:  Cannabis Cannabinoid Res       Date:  2019-12-06

4.  Effects of fixed-interval duration on the development of tolerance to decreased responding by l-nantradol.

Authors:  J B Smith
Journal:  Psychopharmacology (Berl)       Date:  1987       Impact factor: 4.530

5.  Effects of fixed-ratio length on the development of tolerance to decreased responding by l-nantradol.

Authors:  J B Smith
Journal:  Psychopharmacology (Berl)       Date:  1986       Impact factor: 4.530

Review 6.  Cannabinoids in chronic non-cancer pain medicine: moving from the bench to the bedside.

Authors:  H Meng; A Deshpande
Journal:  BJA Educ       Date:  2020-07-21

Review 7.  Pharmacokinetics and pharmacodynamics of cannabinoids.

Authors:  Franjo Grotenhermen
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

8.  Does the cannabinoid dronabinol reduce central pain in multiple sclerosis? Randomised double blind placebo controlled crossover trial.

Authors:  Kristina B Svendsen; Troels S Jensen; Flemming W Bach
Journal:  BMJ       Date:  2004-07-16

Review 9.  Cannabis and psychosis/schizophrenia: human studies.

Authors:  Deepak Cyril D'Souza; Richard Andrew Sewell; Mohini Ranganathan
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2009-07-16       Impact factor: 5.270

Review 10.  Cannabinoid-based medicines for neurological disorders--clinical evidence.

Authors:  Stephen Wright
Journal:  Mol Neurobiol       Date:  2007-06-29       Impact factor: 5.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.